等待開盤 04-01 09:30:00 美东时间
+0.410
+5.90%
今日重点评级关注:瑞穗:维持RELMADA THERAPEUTICS"跑赢大市"评级,目标价从10美元升至19美元;奥本海默:维持Pelthos Therapeutics"跑赢大市"评级,目标价从60美元升至62美元
03-23 13:53
华盛资讯3月20日讯,Bakkt Holdings公布2025财年年度业绩,公司年度营收23.35亿美元,同比下降32.1%,归母净利润亏损1.07亿美元,同比亏损扩大127.7%。
03-20 06:17
今日重点评级关注:花旗:维持Candel Therapeutics"买入"评级,目标价从22美元升至26美元;Chardan Capital:维持CervoMed"买入"评级,目标价从15美元升至21美元
03-19 14:31
Benchmark analyst Mark Palmer maintains Bakkt (NYSE:BKKT) with a Buy and lowers the price target from $40 to $22.
03-18 21:45
Bakkt Holdings, Inc. Class A ( ($BKKT) ) has released a notification of late fi...
03-17 22:21
Bakkt (BKKT) said in an SEC filing on Tuesday that it was unable to timely file its annual report for the year ended December 31, 2025, on Form 10-K. The digital asset services provider attributed the...
03-17 21:18
Bakkt Holdings, Inc. Class A ( ($BKKT) ) just unveiled an announcement. On Marc...
03-17 20:59
华盛资讯3月17日讯,Bakkt Holdings公布2025财年年度业绩,公司年度营收23.35亿美元,同比下降32.1%,归母净利润亏损1.07亿美元,同比亏损扩大129.7%。
03-17 20:47
Companies Reporting Before The Bell • CytomX Therapeutics (NASDAQ:CTMX) is expe...
03-16 19:11
Bakkt Holdings, Inc. Class A ( ($BKKT) ) has issued an update. On February 27, ...
03-03 06:14